Adaptive Biotechnologies has signed an agreement with Biogen Idec for the study of the immune repertoire and immunological biomarkers in hard to treat autoimmune diseases. Adaptive will use its immune profiling assay, immunoSEQ, to characterize the immune repertoire of patient samples with autoimmune disorders with high unmet medical needs. The immunoSEQ assay uses high throughput next-generation sequencing to characterize the repertoire of T and B cell receptors, which can be useful to monitor ...